ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

NCT00752986 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: ZD6474 (Vandetanib at the dose of 100 mg)
DRUG: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
DRUG: Fulvestrant
DRUG: ZD6474 (Vandetanib at the dose of 300 mg)
DRUG: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)

Sponsor

Genzyme, a Sanofi Company